News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

What's Next For Bristol-Myers Squibb (BMY) After Another Opdivo Setback?



8/23/2017 6:17:07 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
The signs were definitely there for a disappointment from Bristol-Myers Squibb. Several weeks ago, AstraZeneca reported its checkpoint inhibitor Imfinzi failed to improve progression-free survival in a late-stage study targeting lung cancer. There were concerns that Bristol-Myers Squibb (BMS) could experience a similar letdown when the company announced results from a late-stage study of its own checkpoint inhibitor, Opdivo, combined with chemotherapy in treating lung cancer.

A disappointment came, but it was in a totally different indication.

Read at Motley Fool


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES